Japanese Foundation for Cancer Research and FRONTEO Healthcare, Inc. Jointly Research Cancer Precision Medicine
(WorldNews Japan)

April 28, 2017 TOKYO, April 28, 2017 (GLOBE NEWSWIRE) -- FRONTEO Healthcare, Inc. (`FRONTEO Healthcare`), a subsidiary of FRONTEO, Inc. (`FRONTEO`) (NASDAQ:FTEO) (TSE:2158) that provides medical data analysis solutions using the artificial intelligence (`AI`) engine `KIBIT` and Japanese Foundation for Cancer Research (`JFCR`) have begun research and development of Cancer Precision Medicine System that may utilize cutting-edge genome analysis technology and AI. Through this research, FRONTEO Healthcare and JFCR aim to develop a cancer precision medicine that will provide the best treatment for each cancer patient based on genetic tests. JFCR established the Cancer Precision Medicine Center in...